Division of Rheumatology, Department of Medicine, Hospital for Special Surgery.
Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Curr Opin Rheumatol. 2021 Sep 1;33(5):431-445. doi: 10.1097/BOR.0000000000000817.
Given the role of inflammation in severe forms of COVID-19, glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) have been assessed as potential COVID-19 therapies.
Randomized controlled trials (RCTs) have shown that glucocorticoids reduce mortality in severe COVID-19. RCTs of DMARDs have shown mixed results varying on intervention and inclusion criteria. DMARDs, including colchicine or biologic agents, may improve COVID-19 outcomes in specific patient populations.
Glucocorticoids are an effective treatment for the management of severe COVID-19. Further studies are needed to better define the patient populations who could benefit from DMARD use, as well as provide guidance regarding the timing of these interventions.
鉴于炎症在严重 COVID-19 中的作用，糖皮质激素和疾病修饰抗风湿药物（DMARDs）已被评估为 COVID-19 的潜在治疗方法。
随机对照试验（RCT）表明，糖皮质激素可降低重症 COVID-19 的死亡率。DMARDs 的 RCT 结果因干预和纳入标准的不同而有所不同。DMARDs，包括秋水仙碱或生物制剂，可能会改善特定患者群体的 COVID-19 结局。
糖皮质激素是治疗严重 COVID-19 的有效方法。需要进一步的研究来更好地确定可能从 DMARD 治疗中获益的患者人群，并为这些干预措施的时机提供指导。
